Fatigue is commonly associated with cancer and its treatments and has a negative impact on patients' ability to tolerate treatments and on their quality of life. This epigenetic characterization of morning fatigue in patients receiving chemotherapy finds biological aging, gene regulatory, and inflammatory processes associated with morning fatigue.

This study analyzed genomic data from 2634 Japanese patients with advanced prostate cancer using the C-CAT database, revealing frequent alterations in genes such as TP53, BRCA2, and AR. Key mutations, particularly in TP53 and pathways like PI3K and MYC signaling, were linked to poorer survival, underscoring the importance of population-specific genomic profiling for personalized treatment strategies.